A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Investigator: Maen Abdelrahim, MD

Study Coordinator: Jose Cruz

Status: Enrolling

ClinicalTrials.gov Number: NCT03656536

Phone: 713.441.4457

Protocol Number: Pro00021476


The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
More to Explore